A phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia

Leukemia Research

Volumn 35, Issue 10, 2011, Pages 1384-1389

  Tsuboi, Kosuke ^a   Yokozawa, Toshiya ^b   Sakura, Toru ^c   Watanabe, Takashi ^d   Fujisawa, Shin ^e   Yamauchi, Takahiro ^f   Uike, Naokuni ^g   Ando, Kiyoshi ^a   Kihara, Rika ^b,h   Tobinai, Kensei ^d   Asou, Hiroya ⁱ   Hotta, Tomomitsu ^b   Miyawaki, Shuichi ^j  

^a TOKAI UNIVERSITY HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c SAISEIKAI MAEBASHI HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^f UNIVERSITY OF FUKUI HOSPITAL   (Japan)

^g NATIONAL KYUSHU CANCER CENTER   (Japan)

^h NAGOYA UNIVERSITY HOSPITAL   (Japan)

ⁱ ASTRAZENECA   (United Kingdom)

^j Tokyo Metropolitan Ohtsuka Hospital   (Japan)

more..

Author keywords

Acute myeloid leukemia; Aurora B kinase inhibitor; AZD1152; Barasertib; Efficacy; Pharmacokinetics; Phase I; Safety

Indexed keywords

BARASERTIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTINUOUS INFUSION; CONTROLLED STUDY; CYSTITIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOPHTHALMITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOKALEMIA; JAPANESE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; PRIORITY JOURNAL; SEPTIC SHOCK; SIDE EFFECT; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; ENZYME INHIBITORS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPENIA; PHOSPHORIC ACID ESTERS; PROTEIN-SERINE-THREONINE KINASES; QUINAZOLINES; TREATMENT OUTCOME;

EID: 80052100694     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.04.008     Document Type: Article

References (32)

1. Burnett A., Wetzler M., Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011, 29:487-494.
2. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007, 25:1908-1915.
3. Löwenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. N Engl J Med 1999, 341:1051-1062.
4. Löwenberg B., Griffin J.D., Tallman M.S. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology 2003, 2003:82-101.
5. Menzin J., Lang K., Earle C.C., Kerney D., Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002, 162:1597-1603.
6. Leith C.P., Kopecky K.J., Godwin J., McConnell T., Slovak M.L., Chen I.M., et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood 1997, 89:3323-3329.
7. Meraldi P., Honda R., Nigg E.A. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev 2004, 14:29-36.
8. Mistry H.B., MacCallum D.E., Jackson R.C., Chaplain M.A., Davidson F.A. Modeling the temporal evolution of the spindle assembly checkpoint and role of Aurora B kinase. Proc Natl Acad Sci USA 2008, 105:20215-20220.
9. Moore A.S., Blagg J., Linardopoulos S., Pearson A.D. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia 2010, 24:671-678.
10. Ota T., Suto S., Katayama H., Han Z.B., Suzuki F., Maeda M., et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res 2002, 62:5168-5177.
11. Kanda A., Kawai H., Suto S., Kitajima S., Sato S., Takata T., et al. Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation. Oncogene 2005, 24:7266-7272.
12. Walsby E., Walsh V., Pepper C., Burnett A., Mills K. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica 2008, 93:662-669.
13. Oke A., Pearce D., Wilkinson R.W., Crafter C., Odedra R., Cavenagh J., et al. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res 2009, 69:4150-4158.
14. Joel S.P., Oke A., Foot N., Keen N., Bonnet D., Lister T.A., et al. The activity of the novel Aurora Kinase B inhibitor AZD1152 in acute myeloid leukaemia cells. Blood 2005, 106:3374.
15. Tomita M., Tanaka Y., Mori N. Aurora kinase inhibitor AZD1152 negatively affects the growth and survival of HTLV-1-infected T lymphocytes in vitro. Int J Cancer 2010, 127:1584-1594.
16. Ikezoe T., Takeuchi T., Yang J., Adachi Y., Nishioka C., Furihata M., et al. Analysis of Aurora B kinase in non-Hodgkin lymphoma. Lab Invest 2009, 89:1364-1373.
17. Wilkinson R.W., Odedra R., Heaton S.P., Wedge S.R., Keen N.J., Crafter C., et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 2007, 13:3682-3688.
18. Boss D.S., Witteveen P.O., van der Sar J., Lolkema M.P., Voest E.E., Stockman P.K., et al. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol 2011, 22:431-437.
19. Löwenberg B., Rousselot P., Martinelli G., Goudie A., Stockman P., Kantarjian H. Phase I/II study to assess the safety and efficacy of the Aurora B kinase inhibitor, AZD1152, in patients with advanced acute myeloid leukemia. Blood 2009, 114(22). [abst. 2080].
20. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003, 21:4642-4649.
21. Steeghs N., Eskens F.A., Gelderblom H., Verweij J., Nortier J.W., Ouwerkerk J., et al. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol 2009, 27:5094-5101.
22. Cohen R.B., Jones S.F., Aggarwal C., von Mehren M., Cheng J., Spigel D.R., et al. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res 2009, 15:6694-6701.
23. Traynor A.M., Hewitt M., Liu G., Flaherty K.T., Clark J., Freedman S.J., et al. Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol 2011, 67:305-314.
24. Plummer E.R., Calvert H., Arkenau H., Mallett K.H., Squires M., Smith D., et al. A dose-escalation and pharmacodynamic study of AT9283 in patients with refractory solid tumours. J Clin Oncol 2008, 26(15S). [abst. 2519].
25. Renshaw J.S., Patnaik A., Gordon M., Beeram M., Fischer D., Gianella-Borradori A., et al. A phase I two arm trial of AS703569 (R763), an orally available aurora kinase inhibitor, in subjects with solid tumors: preliminary results. J Clin Oncol 2007, 25(18S). [abst. 14130].
26. Robert F., Hurwitz H., Verschraegen C.F., Advani R., Berman C., Taverna P., et al. Phase 1 trial of SNS-314, a novel selective inhibitor of aurora kinases A, B, and C, in advanced solid tumor patients. J Clin Oncol 2008, 26(15S). [abst. 14642].
27. Jones S.F., Burris H.A., Dumez H., Infante J.R., Fowst C., Gerletti P., et al. Phase I accelerated dose-escalation, pharmacokinetic (PK) and pharmacodynamic study of PF-03814735, an oral aurora kinase inhibitor, in patients with advanced solid tumors: preliminary results. J Clin Oncol 2008, 26(15S). [abst 2517].
28. Dees E.C., Infante J.R., Burris H.A., Astsaturov I.A., Stinchcombe T., Liu H., et al. Phase I study of the investigational drug MLN8237, an Aurora A kinase (AAK) inhibitor, in patients (pts) with solid tumors. J Clin Oncol 2010, 28(15S). [abst. 3010].
29. Keen N., Brown E., Crafter C., Wilkinson R.W., Wedge S., Foote K.M., et al. Biological characterisation of AZD1152, a highly potent and selective inhibitor of aurora kinase activity. Clin Cancer Res 2005, 11. [abst. B220].
30. Foran J.M., Ravandi F., O'Brien S.M., Borthakur G., Rios M., Boone P., et al. Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia. J Clin Oncol 2008, 26(15S). [abst. 2518].
31. Howard S., Berdini V., Boulstridge J.A., Carr M.G., Cross D.M., Curry J., et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem 2009, 52:379-388.
32. Sonet A., Graux C., Maertens J., Hartog C.-M., Duyster J., Götze K., et al. Phase I, dose-escalation study of 2 dosing regimens of AS703569, an inhibitor of aurora and other kinases, administered orally in patients with advanced hematological malignancies. Blood 2008, 112(11). [abst. 2963].